TGR BioSciences Pty Ltd (TGR) is pleased to announce the award of patent protection for a faster and more sensitive immunoassay. The assay has a wide range of potential applications, from clinical diagnostics to the detection of plant diseases.

TGR’s CaptSure™ technology was granted a US Patent (9,086,407) on 21 July 2015, giving TGR exclusive rights to licence the technology to researchers and manufacturers around the world.

Director of TGR, Dr Michael Crouch, said that CaptSure™ technology improves the performance of standard immunoassays by providing a shorter incubation period without compromising sensitivity or quality.

“CaptSure™ improves both the speed and accuracy of these immunoassays by reducing the number of steps required to carry out a test — this results in less interference when measuring complex samples,” he said.

As opposed to conventional multi-incubation and multi-wash immunoassays, TGR’s CaptSure™ technology format requires only a single incubation and wash step — made possible by incubating the sample with both ‘capture’ and ‘detector’ antibodies at the same time. This reduces the overall assay time significantly compared to conventional assays.

In addition, the CaptSure™ technology also greatly reduces the costs of manufacturing these tests, by simplifying test development as well as reducing the amount of core reagents required.

The award of this new patent means TGR can now broaden its partnerships with other bio-manufacturing companies and laboratories to expand the use of CaptSure™ technology.